Role of proliferation in HER2 status predicted response to doxorubicin

International Journal of Cancer

Volumn 105, Issue 4, 2003, Pages 568-573

  Campiglio, Manuela ^a   Somenzi, Giulia ^a   Olgiati, Clelia ^a   Beretta, Giovanni ^a   Balsari, Andrea ^a   Zaffaroni, Nadia ^a   Valagussa, Pinuccia ^a   Ménard, Sylvie ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast carcinoma; Doxorubicin; HER2; Tumor cells proliferation; Tumor response prediction

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA; CELL DIVISION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; GENES, ERBB-2; HUMANS; NEOADJUVANT THERAPY; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038612855     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11113     Document Type: Article

References (42)

1. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41.
2. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
3. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-60.
4. Paik SM, Bryant J, Park CH, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
5. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537-47.
6. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65-77.
7. Harris LN, Yang L, Tang C, Yang D, Lupu R. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin β-2. Clin Cancer Res 1998;4:1005-12.
8. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993;8:933-8.
9. Keith WN, Douglas F, Wishart GC, McCallum HM, George WD, Kaye SB, Brown R. Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer [A] 1993;29A:1469-75.
10. Murphy DS, McHardy P, Coutts J, Mallon EA, George WD, Kaye SB, Brown R, Keith WN. Interphase cytogenetic analysis of erbB2 and topoIIα co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 1995;64:18-26.
11. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T. Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-16.
12. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J. Amplification and deletion of topoisomerase Ilalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47.
13. Vassetzky YS, Alghisi GC, Roberts E, Gasser SM. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide. Br J Cancer 1996:73:1201-9.
14. Withoff S, Keith WN, Knol AJ, Coutts JC, Hoare SF, Mulder NH, de Vries EG. Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 1996;74:502-7.
15. Zhou Z, Zwelling LA, Kawakami Y, An T, Kobayashi K, Herzog C, Kleinerman ES. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 1999;59:4618-24.
16. Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001;7:1497-504.
17. Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford LJ, Harris AL, Hickson ID. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 1995:72:1454-61.
18. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998;77:2267-73.
19. Ménard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, Cascinelli N. HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 2002;8:520-5.
20. Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G, Melani C, Ménard S. NGF co-operates with p185HER2 in activating growth of human breast carcinoma cells. J Biol Chem 2000;275:5388-94.
21. Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A, Ménard S. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 1998;17:425-32.
22. Centis F, Tagliabue E, Uppugunduri S, Pellegrini R, Martignone S, Mastroianni A, Ménard S, Colnaghi MI. p185 HER2/neu epitope mapping with murine monoclonal antibodies. Hybridoma 1992;11:267-76.
23. Ravdin PM, Green S, Albain KS, Boucher V, Ingle J, Pritchard K, Shepard L, Davidson N, Hayer DF, Clark GM, Martino S, Osborne CK, Allred DC. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuant CAF T with tamoxifen (T) alone. Proc Am Soc Cli Oncol 1998;17:374.
24. Paik S, Park C. HER-2 and choice of adjuvant chemotherapy in breast cancer. Semin Oncol 2001;28:332-5.
25. Moliterni A, Ménard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, Casalini P, Tomasic G, Marubini E, Pilotti S, Bonadonna G. HER2 overexpression and doxorubicin in the adjuvant chemotherapy of resectable breast cancer. J Clin Oncol 2003;21:458-62.
26. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56.
27. Di Leo A, Larsimont D, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Closon-Dejardin MT, Dolci S, Bartholomeus S, et al. CMF or anthracycline-based adjuvant chemotherapy for node-positive (N+) breast cancer (BC) patients (PTS): 4 year results of a Belgian randomised clinical trial with predictive markers analysis. Proc Am Soc Clin Oncol 2000;18:258.
28. Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998;16:470-9.
29. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-21.
30. Field AS, Chamberlain NL, Tran D, Morey AL. Suggestions of HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridization. Pathology 2001;33:278-82.
31. Aas T, Borresen A-L, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-4.
32. Tbakhi A, Totos G, Pettay JD, Myles J, Tubbs RR. The effect of fixation on detection of B-cell clonality by polymerase chain reaction. Mod Pathol 1999;12:272-8.
33. Goodman M. Managing the side effects of chemotherapy. Semin Oncol Nurs 1989;5:29-52.
34. Blijham GH. Prevention and treatment of organ toxicity during high-dose chemotherapy: an overview. Anticancer Drugs 1993;4:527-33.
35. Balsari AL, Morelli D, Ménard S, Veronesi U, Colnaghi MI. Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J 1994;8:226-30.
36. Ménard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000;182:150-62.
37. Bergh J. Clinical studies of p53 in treatment and benefit of breast cancer patients. Endocr Relat Cancer 1999;6:51-9.
38. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
39. Ménard S, Casalini P, Tomasic G, Pilotti S, Cascinelli N, Bufalino R, Perrone F, Longhi C, Rilke F, Colnaghi MI. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat 1999;55:169-77.
40. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, De Mascarel I, Coindre JM. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GSTπ. Br J Cancer 1996;74:1458-65.
41. Aranda FI, Laforga JB. Cellular proliferation in breast ductal infiltrating carcinoma. Correlation with clinical and histopathological variables. Pathol Res Pract 1997;193:683-8.
42. Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J. Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 1999;112: S40-52.